Inhibition of nuclear factor kappaB proteins-platinated DNA interactions correlates with cytotoxic effectiveness of...

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Platinum anticancer drugs target nuclear DNA, influencing cell death and signaling pathways.
• Nuclear factor kappaB (NF-κB) activation is a key signaling pathway affected by platinum drugs.
• NF-κB's biological functions depend on its proteins binding to DNA consensus sequences (κB sites).

Purpose of the Study:

• To investigate how DNA adducts from different platinum complexes affect NF-κB protein binding to κB sites.
• To correlate the structural properties of platinum-induced DNA adducts with their impact on NF-κB binding and cytotoxicity.

Main Methods:

• Gel-mobility-shift assays were used to examine protein-DNA interactions.
• Surface plasmon resonance spectroscopy quantified the affinity of NF-κB proteins to damaged DNA.
• Three platinum complexes with varying cytotoxicity (BBR3464, cisplatin, transplatin) were studied.

Main Results:

• Structurally distinct DNA adducts formed by platinum complexes differentially affected NF-κB binding affinity.
• Highly cytotoxic BBR3464 and less cytotoxic cisplatin showed greater inhibition of NF-κB binding compared to ineffective transplatin.
• The efficiency of inhibiting NF-κB binding correlated with the structural perturbations induced in DNA.

Conclusions:

• Structural perturbations in DNA by platinum(II) complexes correlate with their ability to inhibit NF-κB binding.
• This inhibition of NF-κB binding is linked to the observed anticancer cytotoxicity of platinum drugs.
• Further studies with a broader range of platinum(II) complexes are needed to fully generalize these findings.